Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bioorg Med Chem Lett ; 8(17): 2395-8, 1998 Sep 08.
Artigo em Inglês | MEDLINE | ID: mdl-9873548

RESUMO

A set of biphenyl aminoacid building blocks has been synthesized. These were used to construct partially-peptidic combinatorial libraries as equimolar multi-component samples. Activity of members of this library as vitronectin receptor antagonists is described, together with SAR studies of the most active members. These studies illustrate several important features of combinatorial libraries.


Assuntos
Compostos de Bifenilo/síntese química , Bases de Dados como Assunto , Receptores de Vitronectina/metabolismo , Compostos de Bifenilo/química , Compostos de Bifenilo/farmacocinética , Compostos de Bifenilo/farmacologia , Desenho de Fármacos , Isomerismo , Cinética , Conformação Molecular , Estrutura Molecular , Receptores de Vitronectina/efeitos dos fármacos , Relação Estrutura-Atividade
2.
J Med Chem ; 40(14): 2196-210, 1997 Jul 04.
Artigo em Inglês | MEDLINE | ID: mdl-9216839

RESUMO

Tetracyclic guanines have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compounds are inactive or only weakly active as inhibitors of PDE3, which is a major isozyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound 31, with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while 50, with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compounds 20, 22, 30, and 50 are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compounds 12, 20, and 28 reduced blood pressure by more than 45 mmHg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).


Assuntos
3',5'-AMP Cíclico Fosfodiesterases/antagonistas & inibidores , 3',5'-GMP Cíclico Fosfodiesterases/antagonistas & inibidores , Anti-Hipertensivos/síntese química , Pressão Sanguínea/efeitos dos fármacos , Guanina/análogos & derivados , Guanina/síntese química , Inibidores de Fosfodiesterase/síntese química , Diester Fosfórico Hidrolases , Pirróis , Administração Oral , Animais , Anti-Hipertensivos/química , Anti-Hipertensivos/farmacologia , Nucleotídeo Cíclico Fosfodiesterase do Tipo 1 , Nucleotídeo Cíclico Fosfodiesterase do Tipo 5 , Guanina/química , Guanina/farmacologia , Indicadores e Reagentes , Isoenzimas/antagonistas & inibidores , Cinética , Espectroscopia de Ressonância Magnética , Estrutura Molecular , Inibidores de Fosfodiesterase/química , Inibidores de Fosfodiesterase/farmacologia , Ratos , Ratos Endogâmicos SHR , Relação Estrutura-Atividade
3.
J Med Chem ; 25(1): 12-8, 1982 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-7086815

RESUMO

A novel series of antiinflammatory agents, N-isoxazolyl-3-carboxamides of 4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide, was synthesized and evaluated as antiinflammatory agents in the carrageenin-induced rat paw edema (CIRPE) assay and adjuvant-induced polyarthritis (AIP) assay. Several analogues were found to be equipotent or more potent than aspirin and phenylbutazone. Structure-activity relationships are discussed. One of the compounds, 4-hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine 3-carboxamide 1,1-dioxide (3a; isoxicam), was found to be 3 times as potent as phenylbutazone in the CIRPE and in the therapeutic AIP assays. Isoxicam (3a) is presently undergoing phase III clinical trial as an antiarthritic drug.


Assuntos
Anti-Inflamatórios/farmacologia , Isoxazóis/farmacologia , Oxazóis/farmacologia , Piroxicam/análogos & derivados , Tiazinas/farmacologia , Animais , Anti-Inflamatórios/síntese química , Isoxazóis/síntese química , Masculino , Ratos , Ratos Endogâmicos , Relação Estrutura-Atividade , Tiazinas/síntese química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...